Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains
The DOI matches its Crossref record.
Abstract
High mole ratio BR96 immunoconjugates were synthesized using branched peptide-doxorubicin linkers designed to liberate doxorubicin following antigen-specific internalization into lysosomes. However, these immunoconjugates are highly prone to noncovalent, dimeric aggregation. We hypothesize that this is due to (1) the hydrophobic nature of the peptides, (2) the loss of positive charge upon amide formation at the 3'-amino group of doxorubicin, and (3) the proximity of the peptide hydrophobic residues to form efficient intermolecular stacking interactions. By introducing a hydrophilic methoxytriethylene glycol chain onto the doxorubicin portion of the branched peptide linkers, aggregation has been eliminated or greatly reduced in the immunoconjugate products. The methoxytriethylene glycol chain was linked to the doxorubicin moiety of the linker via a hydrazone bond that is stable at pH 7 but hydrolyzes rapidly at pH 5 to release free drug. BR96 immunoconjugates synthesized from methoxytriethylene glycol-modified branched peptide-doxorubicin linkers are highly potent and immunospecific in vitro. The data suggest that the methoxytriethylene glycol chain hydrolyzes as designed upon antigen-specific internalization into tumor lysosomes in vitro, where enzymatic degradation of the peptide linker releases free doxorubicin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786
Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., & Senter, P. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3212 · Cited by 557
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Analytical methods for physicochemical characterization of antibody drug conjugates
Wakankar, A., Chen, Y., Gokarn, Y., & Jacobson, F. S. (2011) · mAbs · doi:10.4161/mabs.3.2.14960 · Cited by 382
Theory and practice of size exclusion chromatography for the analysis of protein aggregates
Fekete, S., Beck, A., Veuthey, J.-L., & Guillarme, D. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.04.011 · Cited by 324
Prodrug-based intracellular delivery of anticancer agents
Bildstein, L., Dubernet, C., & Couvreur, P. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.12.005 · Cited by 310
Sun, X., Ponte, J. F., Yoder, N. C., Laleau, R., Coccia, J., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00062 · Cited by 277
Killing cancer cells by targeted drug-carrying phage nanomedicines
Bar, H., Yacoby, I., & Benhar, I. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-37 · Cited by 149
“Recently more elaborate drug conjugation schemes, such as the use of dendrimers and branched linkers to increase carrying capacity were devised to maximize the drug payload per targeting molecule that binds a target site [44-46].”
BackgroundDevelopments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
“due to the hydrophobic nature of these peptides [193].”
BackgroundLucas, A. T., Moody, A., Schorzman, A. N., & Zamboni, W. C. (2021) · Antibodies · doi:10.3390/antib10030030 · Cited by 40
Huang, R., Sun, Y., Zhang, X.-Y., Sun, B.-W., Wang, Q.-C., & Zhu, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.05.013 · Cited by 21
Metadata
- Authors
- King, H. D., Dubowchik, G. M., Mastalerz, H., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., & Trail, P. A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-08-14
- Volume
- 45
- Issue
- 19
- Pages
- 4336-4343
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2035714004
- Cited by
- 135
- References
- 0
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.